TERT and cancer: Mutually exclusive somatic TERT promoter mutations, C250T, C228T and CC242TT, were found in 48% (10/21) of the melanoma cohort and increased the overall ctDNA detection rate from 67%, based on detection of driver (NRAS or BRAF) or cancer-associated mutations, to 71%.